Features Partner Sites Information LinkXpress
Sign In
Demo Company

Rose Bengal-Based Drug Kills Both Primary and Secondary Melanoma Tumors

By BiotechDaily International staff writers
Posted on 02 Sep 2013
Print article
Drug developers have discovered the immunological mechanism that underlies the ability of the candidate drug PV-10 to induce regression of primary and secondary melanoma tumors.

PV-10, which was developed by Provectus Pharmaceuticals, Inc., (Knoxville, TN, USA) is a 10% solution of Rose Bengal formulated for IL (intralesional) injection. Rose Bengal is a water-soluble xanthene dye that had been previously employed in liver function studies and is still in use by ophthalmologists.

Investigators at the Moffitt Cancer Center (Tampa, FL, USA) worked with two different mouse models: BALB/c mice bearing MT-901 breast cancer and C57BL/6 mice that had been injected with B16 melanoma cells to establish one subcutaneous primary tumor and multiple secondary lung lesions.

Results published in the July 17, 2013, online edition of the journal PLOS ONE revealed that treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases.

Splenocytes isolated from tumor bearing mice treated with IL PV-10 demonstrated enhanced tumor-specific IFN-gamma (interferon-gamma) production compared to splenocytes from saline-treated mice in both models. In addition, a significant increase in lysis of B16 cells by T-cells isolated after PV-10 treatment was observed. Transfer of T-cells isolated from tumor-bearing mice treated with IL PV-10 led to tumor regression in untreated mice bearing B16 melanoma.

The investigators concluded that these studies established that IL PV-10 therapy induced tumor-specific T-cell-mediated immunity, which supported the concept of combining IL PV-10 with immunotherapy for advanced malignancies. “Various injection therapies for melanoma have been examined over the past 40 years, but few have shown the promising results we are seeing with PV-10,” said senior author Dr. Shari Pilon-Thomas, assistant member of the immunology program at the Moffitt Cancer Center.

Related Links:
Provectus Pharmaceuticals, Inc.
Moffitt Cancer Center

Print article



view channel
Image: Sequencing and analysis of the pineapple genome offers new insights into the evolution of plant drought-resistance, different types of photosynthesis, and circadian clock regulatory adaptations (Photo courtesy of Robert E. Paull, University of Hawaii).

Insights into Evolution of Drought-Tolerance Revealed by Pineapple Genome

Upon sequencing its genome, scientists begin to home in on genes and pathways that enable the pineapple plant to thrive in water-limited environments and open a new window on CAM photosynthesis, circadian... Read more


view channel
Image: A partially completed three-dimensional printed airway from nostril to trachea with fine structure of the nasal cavity showing (Photo courtesy of Dr. Rui Ni, Pennsylvania State University).

The Structure of the Nasal Cavity Channels Food Smells into the Nose and Avoids the Lungs

Three-dimensional printing technology was used to create a model of the nasal cavity that enabled researchers to demonstrate why the smell of food goes into the nose rather than down into the lungs.... Read more


view channel
Image: Structure of the protein encoded by the CFTR gene (Photo courtesy of Wikimedia Commons).

Advanced Gene Therapy Cures Cystic Fibrosis in Culture and Mouse Models

Improvements in gene therapy technology enabled restoration of ion channel function in cultures of cells from cystic fibrosis (CF) patients and in a CF mouse model. In cystic fibrosis, mutations of... Read more

Lab Technologies

view channel
Image:  The BioSpa 8 Automated Incubator (Photo courtesy of BioTek Instruments).

Smart Incubator System Automates Live Cell Assay Operations

A new instrument that automates laboratory workflow by linking microplate washers and dispensers with readers and imaging systems is now available for biotech and other life sciences researchers.... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.